*September 2025*
In this episode of LungCancerRx, the experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Recorded onsite in Barcelona, Spain, cohost Eric Singhi, MD, from Houston, Texas, is joined by Bruna Pellini, MD, from Moffitt Cancer Center and Research Institute in Tampa, Florida; Antonio Calles, MD, from Hospital General Universitario Gregorio Marañón in Madrid, Spain; and Stephen Liu, MD, from Lombardi Comprehensive Cancer Center of Georgetown University in Washington, DC. “With FLAURA2… we do see an improvement in survival – a meaningful improvement in survival,” Dr. Liu said. The panelists share how they will talk with patients about the results and why, even with overall survival benefit, the conversations are nuanced and must take into account patients’ goals, lifestyle, and general health. “I’m the expert on the treatments, but they are the experts on their lives,” Dr. Calles said. Watch video here.
